INTRODUCTION
Clostridium difficile infection (CDI) is a significant public health problem, associated with increasing morbidity, mortality, and health care-related costs in the United States and around the globe (
1). Current treatment for patients with CDI includes the antibiotics vancomycin and metronidazole; however, even after successful treatment, this therapy is associated with more than 20% of cases relapsing (
2–5). Even though antibiotics are the first line of treatment, they are also key risk factors in the pathogenesis of CDI (
6,
7). Antibiotics alter the resident gut microbiota, decreasing resistance against
C. difficile colonization (
8–10). However, the exact mechanism for colonization resistance is still unknown.
By altering the gut microbiota, antibiotics ultimately change the gut metabolome (
11,
12), specifically the composition and concentration of bile acids (
11,
13–15). Bile acids are synthesized by hepatic enzymes from cholesterol and are important for lipoprotein, glucose, drug, and energy metabolism (
16,
17). Mice synthesize two primary bile acids, cholate (CA) and β-muricholate (βMCA), whereas humans synthesize CA and chendeoxycholate (CDCA) (
18). Bile acids are further conjugated with taurine and glycine (
19). Once made in the liver, 95% of primary bile acids, both unconjugated and conjugated, are absorbed in the terminal ileum and through the hepatic system (
16,
18). Primary bile acids that make it to the large intestine are biotransformed by members of the gut microbiota via two enzymatic reactions, deconjugation and dehydroxylation, into secondary bile acids, including ω-muricholate (ωMCA), hyodeoxycholate (HDCA), ursodeoxycholate, (UDCA), lithocholate (LCA), and deoxycholate (DCA) (
16,
20,
21).
C. difficile is a spore-forming organism that requires specific bile acids for maximal germination into a metabolically active vegetative cell, where it can grow to high cell density and produce toxins (
22–24). However, many microbially derived secondary bile acids inhibit
C. difficile growth (
22,
25,
26). Specific bile acids are able to enhance or inhibit
C. difficile spore germination and vegetative cell outgrowth
in vitro, and this is thought to be important for colonization resistance against
C. difficile. Wilson et al. first suggested this concept in 1983, and more recent data support this hypothesis (
25,
27–30). Multiple studies showing that restoration of secondary bile acids by members of the gut microbiota help restore colonization resistance against
C. difficile in humans and in mice have been published recently (
12,
28,
29). However, most studies defining the dynamics between
C. difficile and bile acids have been done
in vitro, and it is not clear how physiologically relevant this is
in vivo (
22). Based on our previous work and work by others, we hypothesize that antibiotics associated with decreased colonization resistance against
C. difficile in the gut not only alter the gut microbiota but also decrease secondary bile acid pools, allowing for
C. difficile spore germination and outgrowth. To test this hypothesis, we used a variety of antibiotics to create distinct microbial and metabolic (bile acid) environments in the murine gut and directly tested their ability to support or inhibit
C. difficile spore germination and outgrowth
ex vivo. Here we show that susceptibility to C. difficile spore germination and outgrowth occurs in murine small intestinal content (ileum) regardless of antibiotic perturbation. Susceptibility to C. difficile spore germination and outgrowth in the large intestine (cecum) was present only after specific broad-spectrum antibiotic treatment (cefoperazone, clindamycin, and vancomycin) and was accompanied by a loss of secondary bile acids and significant changes to the gut microbiota. In vivo concentrations of secondary bile acids present during C. difficile resistance were able to inhibit spore germination and outgrowth in vitro. This study illustrates how antibiotics associated with increased risk of CDI are able to alter the gut microbiota, which more importantly results in a loss of secondary bile acid production, allowing for C. difficile colonization. Understanding how the gut microbiota regulates bile acids in both the small and large intestines is vital for designing future therapies to restore colonization resistance against C. difficile and for other metabolic disorders, including obesity and diabetes.
DISCUSSION
Using a targeted metabolomics approach, we defined the
in vivo concentrations of bile acids before and after various antibiotic treatments in the murine small and large intestines.
C. difficile spores were able to germinate and outgrow in most ileal content and cecal content that was depleted of secondary bile acids and had significant alterations to the microbiome. To further define the mechanism of colonization resistance against
C. difficile, we conducted
in vitro studies to show that
in vivo concentrations of secondary bile acids were able to inhibit spore germination and growth in the large intestine. Previous
in vitro studies looking at the interaction between bile acids and
C. difficile spore germination and growth observed inhibition of germination with ωMCA, LCA, and UDCA and inhibition of growth with ωMCA, LCA, and DCA (
12,
22,
25,
26,
28,
32,
33). However, they were not based on
in vivo bile acid levels in the gastrointestinal (GI) tract. Newer, more sensitive mass spectrometric technology has allowed us to define the real-time physiological concentrations
in vivo as opposed to untargeted metabolomic approaches, which only yield relative abundance (
34). Defining the composition and concentration of bile acids that are able to inhibit or enhance
C. difficile spore germination and outgrowth in the gut is critical for the development of targeted bacterial therapeutics to prevent
C. difficile.
Interestingly, we observed that
C. difficile spores were able to germinate in ileal content of the mouse before and after antibiotic treatment. Germination has been demonstrated in the small intestine in other rodent models (
31,
35,
36). Although primary bile acids are absorbed in the small intestine, it is likely that sufficient levels are present to allow some level of spore germination. We detected consistently high levels of the germinants TCA and CA, even in the absence of antibiotic treatment, a finding that has been reported previously (
14). It is hard to say what the concentration of primary bile acids is in the human small intestine because collection of such samples is difficult, although we know that human serum is rich in primary bile acids, which are mostly absorbed in the small intestine (
37).
It is also challenging to say what the oxygen content is in the small intestine. Multiple studies measuring oxygen tension in the small intestine of rats, sheep, ducks, and mice show a spatial distribution, where the mucosa is more oxygen rich and the lumen is more anaerobic (
38–40). More recent literature using sensitive oxygen-measuring imaging found the ileum in a mouse, which is relevant to our model, to be quite anaerobic and to resemble that of the colon (
38). Similarly, the oxygen concentrations in the duck small intestinal lumen measured by microelectrodes were 25 mm Hg closest to the villi and <0.5 mm Hg in the center of the lumen (
39). This further supports that the luminal content of the ileum is anaerobic. This study and our previous work also suggest that spores will always germinate to some degree in small intestinal content (
31). Therefore, prevention of
C. difficile from growing in the cecum and large intestine will be critical.
In the cecum, we observed that specific antibiotic treatments (cefoperazone, vancomycin, and clindamycin) altered the gut microbiome and decreased the secondary bile acid load, allowing
C. difficile to germinate and outgrow. Some of these antibiotics are associated with susceptibility to CDI, with the highest risk associated with cephalosporin, clindamycin, penicillin, and fluoroquinolones (
7,
41,
42). Interestingly, vancomycin is the preferred treatment for CDI but has been shown to alter the microbiome, bile acid metabolism, and host physiology in both mice and humans (
13,
15,
43–45).
In our study, bacterial members from the
Firmicutes phylum, specifically the
Lachnospiraceae and
Ruminococcaceae families, were positively correlated with secondary bile acids in the cecum and resistance to
C. difficile. A small subset of spore-forming, anaerobic members of the class
Clostridia are able to perform enzymatic reactions on conjugated bile acids, including deconjugation and 7α-dehydroxylation, which is a multistep biotransformation from CA to DCA and CDCA to LCA (
16,
17,
20,
46). Well-characterized bacteria that have 7α-dehydroxylation activity are from the
Clostridium species and include
Clostridium scindens,
Clostridium hiranonis,
Clostridium hylemonae, and
Clostridium sordellii, which belong to the
Blautia,
Ruminococcaceae, and
Lachnospiraceae families (
46–48). Most recently there is renewed interest in
C. scindens because of its high 7α-dehydroxylation activity and its presence in patients’ resistant to
C. difficile (
25,
28). Future therapies to restore colonization resistance against
C. difficile could potentially include targeted bacterial cocktails that are able to restore the level of secondary bile acids in the large intestine to inhibit
C. difficile (
28,
49). Much attention has focused on increasing DCA levels in the gut. However, increased levels of DCA are associated with an increased risk of colon cancer (
50,
51). This study identifies new secondary bile acid targets (LCA, UDCA, HDCA, and ωMCA) at inhibitory concentrations, which could be produced by bacterial therapies to inhibit
C. difficile.
Bacterial members from the
Proteobacteria and
Firmicutes phyla, more specifically from the
Enterobacteriaceae and
Lactobacillaceae families, were negatively correlated with secondary bile acids in this study. This is consistent with another study in which blooms of proinflammatory
Enterobacteriaceae were found in cirrhotic patients and corresponded with a decrease in fecal bile acid levels (
52). It is not known whether members from the
Proteobacteria phylum are sensitive to the antimicrobial properties of secondary bile acids, but it has been suggested that they may limit their growth in the gut. Members of the
Lactobacillaceae family include many
Lactobacillus species, and they contain potent bile salt hydrolases, which are able to deconjugate glycine- or taurine-conjugated bile acids into unconjugated bile acids (
53,
54). The lack of bacteria able to make secondary bile acids after antibiotics would cause a buildup of primary bile acids like TCA and CA, which are germinants of
C. difficile spores.
More recently, human studies have shown recovery of fecal secondary bile acids, and members from the class
Clostridia, including members from the
Lachnospiraceae family, were associated with successful fecal transplantation in patients with recurrent CDI (
29,
55). Even though this is promising, spore germination and colonization occurs upstream of the feces. The current standard of measuring the gut microbiota structure is via feces collection, and it is difficult to collect samples from the more relevant upper human GI tract for studying
C. difficile. Although the bile acid profile of mice differs from that of humans, an animal model of CDI allows for the assessment of bile acid concentrations throughout the GI tract (
31). More promising is the observation that more sensitive bile acid metabolomics, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays, are seeing similar bile acid species in both human and mouse sera (
37), suggesting the usefulness of this mouse model.
Finally, there are potential limitations to the present study, including the use of
C. difficile VPI 10463, which is still used in many studies today, although it is not a clinically relevant strain (
8,
28,
31). This strain still provides us with a reproducible model of
C. difficile infection in the mouse. Moving forward, these observations need to be validated with clinically relevant strains as they use a wide range of bile acids for germination (
56,
57). The
ex vivo approach we used is powerful, but it does not account for transit time in the GI tract, as it is a static sample. Even though bile acids are able to inhibit spore germination and the growth rate of
C. difficile in the gut, bile acids do not represent the sole mechanism for colonization resistance against
C. difficile. Other factors that could contribute to colonization resistance in the gut and in our
ex vivo samples include competition for nutrients by other members of the gut microbiota.
Since alterations in the gut microbiome and bile acid metabolism are associated with many diseases, including diabetes, obesity, cancer, and metabolic syndrome (
21,
50,
51,
58), further investigation is needed to understand the complex relationship between the gut microbiota, bile acids, and host physiology.